Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Published:2021-09 Issue: Volume: Page:
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Holekamp Nancy M.,Campochiaro Peter A.,Chang Margaret A.,Miller Daniel^ORCID,Pieramici Dante^ORCID,Adamis Anthony P.,Brittain Christopher,Evans Erica,Kaufman Derrick,Maass Katie F.,Patel Shienal,Ranade Shrirang^ORCID,Singh Natasha,Barteselli Giulio^ORCID,Regillo Carl

Funder

Genentech

Publisher

Elsevier BV

Subject

Ophthalmology

Reference27 articles.

1. Age-related macular degeneration;Mitchell;Lancet,2018

2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration;Li;Cochrane Database Syst Rev,2020

3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration;Solomon;Cochrane Database Syst Rev,2014

4. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA);Schmidt-Erfurth;Br J Ophthalmol,2014

5. Real-world outcomes of anti–vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States;Ciulla;Ophthalmol Retina,2018

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions;Survey of Ophthalmology;2024-11

2. Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study;Ophthalmology Science;2024-11

3. Approved treatments for neovascular age-related macular degeneration: current safety and future directions;Expert Opinion on Drug Safety;2024-08-05

4. Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants;Ophthalmology and Therapy;2024-08-01

5. Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2024-08